Prior to its inclusion in the Trump administration's Operation Warp Speed scheme for the rapid deployment of Wuhan coronavirus (Covid-19) "vaccines," Moderna agreed to pay the U.S. National Institutes of Health (NIH) $400 million to license the spike protein technology the company use